{"id":"camylofin","rwe":[{"pmid":"41133129","year":"2025","title":"Developing and Validating a Robust RP-HPLC Method for Metoclopramide and Camylofin Simultaneous Analysis Using Response Surface Methodology.","finding":"","journal":"International journal of analytical chemistry","studyType":"Clinical Study"},{"pmid":"39568060","year":"2024","title":"Simultaneously quantifying a novel five-component anti- migraine formulation containing ergotamine, propyphenazone, caffeine, camylofin, and mecloxamine using UV spectrophotometry and chemometric models.","finding":"","journal":"BMC chemistry","studyType":"Clinical Study"},{"pmid":"38254447","year":"2024","title":"Integrated Microbiome and Serum Metabolome Analysis Reveals Molecular Regulatory Mechanisms of the Average Daily Weight Gain of Yorkshire Pigs.","finding":"","journal":"Animals : an open access journal from MDPI","studyType":"Clinical Study"},{"pmid":"33417640","year":"2020","title":"Effectiveness and Safety of Camylofin in Augmentation of Labor: A Systematic Review and Meta-Analysis.","finding":"","journal":"Journal of obstetrics and gynaecology of India","studyType":"Clinical Study"},{"pmid":"24179892","year":"2013","title":"To compare the effect of camylofin dihydrochloride (anafortin) with combination of valethamate bromide (epidosin) and hyoscine butyl-N-bormide (buscopan) on cervical dilation.","finding":"","journal":"Journal of clinical and diagnostic research : JCDR","studyType":"Clinical Study"}],"tags":[{"label":"camylofin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 22 member 1","category":"target"},{"label":"SLC22A1","category":"gene"},{"label":"A03AA03","category":"atc"},{"label":"Active","category":"status"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"acamylophenine","offLabel":[],"synonyms":["camylofin","camylofine","camylofine chlorhydrate","acamylophenine","acamylophenine hydrochloride","camylofin hydrochloride","camylofin dihydrochloride"],"timeline":[],"brandName":"Acamylophenine","ecosystem":[],"mechanism":{"target":"Solute carrier family 22 member 1","targets":[{"gene":"SLC22A1","source":"DrugCentral","target":"Solute carrier family 22 member 1","protein":"Solute carrier family 22 member 1"}],"modality":"Small Molecule","drugClass":"camylofin","explanation":"Think of it like a key fitting into a lock. Camylofin is the key that binds to a specific protein, called solute carrier family 22 member 1, and helps to regulate its activity. This can have a variety of effects on the body, depending on the specific protein and its role in different cells and tissues.","oneSentence":"Camylofin works by binding to and modulating the activity of the solute carrier family 22 member 1 protein.","technicalDetail":"Camylofin binds to the solute carrier family 22 member 1 protein, which is a type of transporter that helps to move molecules across cell membranes. By modulating the activity of this protein, Camylofin may be able to influence the levels of certain substances in the body, such as neurotransmitters or hormones."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Camylofin","title":"Camylofin","extract":"Camylofin is an antimuscarinic drug."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/472","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CAMYLOFIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Camylofin","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:08:28.183261","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:49:03.697140+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"oxyphencyclimine","drugSlug":"oxyphencyclimine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dicycloverine","drugSlug":"dicycloverine","fdaApproval":"1950-05-11","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"camylofin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"oxyphencyclimine","brandName":"oxyphencyclimine","genericName":"oxyphencyclimine","approvalYear":"","relationship":"same-class"},{"drugId":"dicycloverine","brandName":"dicycloverine","genericName":"dicycloverine","approvalYear":"1950","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005296","UNII":"340B6Q764V","CHEBI":"CHEBI:95216","INN_ID":"1182","RXNORM":"20136","UMLSCUI":"C0054568","ChEMBL_ID":"CHEMBL253592","KEGG_DRUG":"D01759","DRUGBANK_ID":"DB13738","PUBCHEM_CID":"5902","SECONDARY_CAS_RN":"5892-41-1","MESH_SUPPLEMENTAL_RECORD_UI":"C004644"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AA03","allCodes":["A03AA03","A03DA05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"41133129","title":"Developing and Validating a Robust RP-HPLC Method for Metoclopramide and Camylofin Simultaneous Analysis Using Response Surface Methodology.","journal":"International journal of analytical chemistry"},{"date":"2024 Nov 20","pmid":"39568060","title":"Simultaneously quantifying a novel five-component anti- migraine formulation containing ergotamine, propyphenazone, caffeine, camylofin, and mecloxamine using UV spectrophotometry and chemometric models.","journal":"BMC chemistry"},{"date":"2024 Jan 16","pmid":"38254447","title":"Integrated Microbiome and Serum Metabolome Analysis Reveals Molecular Regulatory Mechanisms of the Average Daily Weight Gain of Yorkshire Pigs.","journal":"Animals : an open access journal from MDPI"},{"date":"2020 Dec","pmid":"33417640","title":"Effectiveness and Safety of Camylofin in Augmentation of Labor: A Systematic Review and Meta-Analysis.","journal":"Journal of obstetrics and gynaecology of India"},{"date":"2013 Sep","pmid":"24179892","title":"To compare the effect of camylofin dihydrochloride (anafortin) with combination of valethamate bromide (epidosin) and hyoscine butyl-N-bormide (buscopan) on cervical dilation.","journal":"Journal of clinical and diagnostic research : JCDR"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acamylophenine, also known as Camylofin, is a small molecule drug that targets the solute carrier family 22 member 1. It is classified as a camylofin drug, but its commercial status and approved indications are unknown. The mechanism of action of Camylofin is not well-documented, but it is believed to work by modulating the activity of its target protein. Further research is needed to fully understand its therapeutic potential and safety profile.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:49:03.697140+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}